Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Icotinib
1.2.3 Gefitinib
1.2.4 Erlotinib
1.2.5 Afatinib
1.2.6 Osimertinib
1.2.7 Brigatinib
1.2.8 Others
1.3 Market by Application
1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Perspective (2020-2031)
2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Revenue (2020-2025)
3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2024
3.5 Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC Head office and Area Served
3.6 Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC, Product and Application
3.7 Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031)
5 Targeted Drug EGFR RTK Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
6.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
6.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
7.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
9.2 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
9.4 Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Beta Pharma
11.1.1 Beta Pharma Company Details
11.1.2 Beta Pharma Business Overview
11.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.1.5 Beta Pharma Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Natco Pharma
11.3.1 Natco Pharma Company Details
11.3.2 Natco Pharma Business Overview
11.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.3.5 Natco Pharma Recent Development
11.4 Qilu Pharmaceutical
11.4.1 Qilu Pharmaceutical Company Details
11.4.2 Qilu Pharmaceutical Business Overview
11.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.4.5 Qilu Pharmaceutical Recent Development
11.5 Genentech (Roche Group)
11.5.1 Genentech (Roche Group) Company Details
11.5.2 Genentech (Roche Group) Business Overview
11.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.5.5 Genentech (Roche Group) Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.6.5 Mylan Recent Development
11.7 Teva
11.7.1 Teva Company Details
11.7.2 Teva Business Overview
11.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.7.5 Teva Recent Development
11.8 OSI Pharmaceuticals
11.8.1 OSI Pharmaceuticals Company Details
11.8.2 OSI Pharmaceuticals Business Overview
11.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.8.5 OSI Pharmaceuticals Recent Development
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Details
11.9.2 Glenmark Pharmaceuticals Business Overview
11.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.9.5 Glenmark Pharmaceuticals Recent Development
11.10 Beacon Pharmaceuticals
11.10.1 Beacon Pharmaceuticals Company Details
11.10.2 Beacon Pharmaceuticals Business Overview
11.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.10.5 Beacon Pharmaceuticals Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Details
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.11.4 Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.12.4 Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.12.5 Pfizer Recent Development
11.13 ARIAD Pharmaceuticals (Takeda)
11.13.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.13.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.13.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.13.5 ARIAD Pharmaceuticals (Takeda) Recent Development
11.14 Genvio Pharma Limited
11.14.1 Genvio Pharma Limited Company Details
11.14.2 Genvio Pharma Limited Business Overview
11.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.14.4 Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.14.5 Genvio Pharma Limited Recent Development
11.15 Drug International Limted
11.15.1 Drug International Limted Company Details
11.15.2 Drug International Limted Business Overview
11.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.15.4 Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.15.5 Drug International Limted Recent Development
11.16 Everest Pharmaceuticals
11.16.1 Everest Pharmaceuticals Company Details
11.16.2 Everest Pharmaceuticals Business Overview
11.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.16.4 Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.16.5 Everest Pharmaceuticals Recent Development
11.17 Incepta Pharmaceuticals Limited
11.17.1 Incepta Pharmaceuticals Limited Company Details
11.17.2 Incepta Pharmaceuticals Limited Business Overview
11.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.17.4 Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.17.5 Incepta Pharmaceuticals Limited Recent Development
11.18 Cipla Pharma
11.18.1 Cipla Pharma Company Details
11.18.2 Cipla Pharma Business Overview
11.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.18.4 Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.18.5 Cipla Pharma Recent Development
11.19 Dr Reddy's Laboratories
11.19.1 Dr Reddy's Laboratories Company Details
11.19.2 Dr Reddy's Laboratories Business Overview
11.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.19.4 Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.19.5 Dr Reddy's Laboratories Recent Development
11.20 Zydus Cadila
11.20.1 Zydus Cadila Company Details
11.20.2 Zydus Cadila Business Overview
11.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.20.4 Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.20.5 Zydus Cadila Recent Development
11.21 Hetero Drugs
11.21.1 Hetero Drugs Company Details
11.21.2 Hetero Drugs Business Overview
11.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.21.4 Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.21.5 Hetero Drugs Recent Development
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Details
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.22.4 Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.22.5 Intas Pharmaceuticals Recent Development
11.23 Alkem Laboratories
11.23.1 Alkem Laboratories Company Details
11.23.2 Alkem Laboratories Business Overview
11.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.23.4 Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.23.5 Alkem Laboratories Recent Development
11.24 RPG Life Sciences
11.24.1 RPG Life Sciences Company Details
11.24.2 RPG Life Sciences Business Overview
11.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.24.4 RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.24.5 RPG Life Sciences Recent Development
11.25 Fresenius Kabi India
11.25.1 Fresenius Kabi India Company Details
11.25.2 Fresenius Kabi India Business Overview
11.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
11.25.4 Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
11.25.5 Fresenius Kabi India Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Icotinib
Table 3. Key Players of Gefitinib
Table 4. Key Players of Erlotinib
Table 5. Key Players of Afatinib
Table 6. Key Players of Osimertinib
Table 7. Key Players of Brigatinib
Table 8. Key Players of Others
Table 9. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2020-2025)
Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2026-2031)
Table 15. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
Table 16. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
Table 17. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
Table 18. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
Table 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players (2020-2025)
Table 21. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2024)
Table 22. Ranking of Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC, Headquarters and Area Served
Table 25. Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC, Product and Application
Table 26. Global Key Players of Targeted Drug EGFR RTK Inhibitors for NSCLC, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2020-2025)
Table 30. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Type (2026-2031)
Table 32. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2020-2025)
Table 34. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2026-2031)
Table 36. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
Table 51. Beta Pharma Company Details
Table 52. Beta Pharma Business Overview
Table 53. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 54. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 55. Beta Pharma Recent Development
Table 56. AstraZeneca Company Details
Table 57. AstraZeneca Business Overview
Table 58. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 59. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 60. AstraZeneca Recent Development
Table 61. Natco Pharma Company Details
Table 62. Natco Pharma Business Overview
Table 63. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 64. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 65. Natco Pharma Recent Development
Table 66. Qilu Pharmaceutical Company Details
Table 67. Qilu Pharmaceutical Business Overview
Table 68. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 69. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 70. Qilu Pharmaceutical Recent Development
Table 71. Genentech (Roche Group) Company Details
Table 72. Genentech (Roche Group) Business Overview
Table 73. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 74. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 75. Genentech (Roche Group) Recent Development
Table 76. Mylan Company Details
Table 77. Mylan Business Overview
Table 78. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 79. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 80. Mylan Recent Development
Table 81. Teva Company Details
Table 82. Teva Business Overview
Table 83. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 84. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 85. Teva Recent Development
Table 86. OSI Pharmaceuticals Company Details
Table 87. OSI Pharmaceuticals Business Overview
Table 88. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 89. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 90. OSI Pharmaceuticals Recent Development
Table 91. Glenmark Pharmaceuticals Company Details
Table 92. Glenmark Pharmaceuticals Business Overview
Table 93. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 94. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 95. Glenmark Pharmaceuticals Recent Development
Table 96. Beacon Pharmaceuticals Company Details
Table 97. Beacon Pharmaceuticals Business Overview
Table 98. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 99. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 100. Beacon Pharmaceuticals Recent Development
Table 101. Boehringer Ingelheim Company Details
Table 102. Boehringer Ingelheim Business Overview
Table 103. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 104. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 105. Boehringer Ingelheim Recent Development
Table 106. Pfizer Company Details
Table 107. Pfizer Business Overview
Table 108. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 109. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 110. Pfizer Recent Development
Table 111. ARIAD Pharmaceuticals (Takeda) Company Details
Table 112. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 113. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 114. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 115. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 116. Genvio Pharma Limited Company Details
Table 117. Genvio Pharma Limited Business Overview
Table 118. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 119. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 120. Genvio Pharma Limited Recent Development
Table 121. Drug International Limted Company Details
Table 122. Drug International Limted Business Overview
Table 123. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 124. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 125. Drug International Limted Recent Development
Table 126. Everest Pharmaceuticals Company Details
Table 127. Everest Pharmaceuticals Business Overview
Table 128. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 129. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 130. Everest Pharmaceuticals Recent Development
Table 131. Incepta Pharmaceuticals Limited Company Details
Table 132. Incepta Pharmaceuticals Limited Business Overview
Table 133. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 134. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 135. Incepta Pharmaceuticals Limited Recent Development
Table 136. Cipla Pharma Company Details
Table 137. Cipla Pharma Business Overview
Table 138. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 139. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 140. Cipla Pharma Recent Development
Table 141. Dr Reddy's Laboratories Company Details
Table 142. Dr Reddy's Laboratories Business Overview
Table 143. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 144. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 145. Dr Reddy's Laboratories Recent Development
Table 146. Zydus Cadila Company Details
Table 147. Zydus Cadila Business Overview
Table 148. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 149. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 150. Zydus Cadila Recent Development
Table 151. Hetero Drugs Company Details
Table 152. Hetero Drugs Business Overview
Table 153. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 154. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 155. Hetero Drugs Recent Development
Table 156. Intas Pharmaceuticals Company Details
Table 157. Intas Pharmaceuticals Business Overview
Table 158. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 159. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 160. Intas Pharmaceuticals Recent Development
Table 161. Alkem Laboratories Company Details
Table 162. Alkem Laboratories Business Overview
Table 163. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 164. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 165. Alkem Laboratories Recent Development
Table 166. RPG Life Sciences Company Details
Table 167. RPG Life Sciences Business Overview
Table 168. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 169. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 170. RPG Life Sciences Recent Development
Table 171. Fresenius Kabi India Company Details
Table 172. Fresenius Kabi India Business Overview
Table 173. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product
Table 174. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
Table 175. Fresenius Kabi India Recent Development
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
Table 179. Authors List of This Report


List of Figures
Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type: 2024 VS 2031
Figure 4. Icotinib Features
Figure 5. Gefitinib Features
Figure 6. Erlotinib Features
Figure 7. Afatinib Features
Figure 8. Osimertinib Features
Figure 9. Brigatinib Features
Figure 10. Others Features
Figure 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2020-2031) & (US$ Million)
Figure 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application: 2024 VS 2031
Figure 13. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 14. Adenocarcinoma of NSCLC Case Studies
Figure 15. Large Cell Carcinoma of NSCLC Case Studies
Figure 16. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 18. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 19. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region: 2024 VS 2031
Figure 20. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Players in 2024
Figure 21. Global Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2024)
Figure 22. The Top 10 and 5 Players Market Share by Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue in 2024
Figure 23. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 25. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 29. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Nordic Countries Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Region (2020-2031)
Figure 37. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 45. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Country (2020-2031)
Figure 49. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 53. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 54. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 55. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 56. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 57. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 58. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 59. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 60. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 61. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 62. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 63. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 64. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 65. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 66. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 67. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 68. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 69. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 70. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 71. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 72. Hetero Drugs Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 73. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 74. Alkem Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 75. RPG Life Sciences Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 76. Fresenius Kabi India Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2020-2025)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit